NEW YORK – Biocept said Thursday that it entered into a securities purchase agreement on March 4 with several institutional investors for the issuance and sale of 16,000,000 shares of its common stock at a price of $.41 per share, for gross proceeds of approximately $6.6 million in a registered direct offering priced at the market.